NAFLD and cardiovascular diseases: a clinical review
P Kasper, A Martin, S Lang, F Kuetting… - Clinical research in …, 2021 - Springer
Non-alcoholic fatty liver DISEASE (NAFLD) is the most common chronic liver disease in
Western countries and affects approximately 25% of the adult population. Since NAFLD is …
Western countries and affects approximately 25% of the adult population. Since NAFLD is …
Effects of SGLT2 inhibitors on kidney and cardiovascular function
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …
Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies
Diabetic kidney disease (DKD) occurs in∼ 40% of patients with diabetes and causes kidney
failure, cardiovascular disease, and premature death. We analyzed the response of a …
failure, cardiovascular disease, and premature death. We analyzed the response of a …
[HTML][HTML] Cardiovascular and renal outcomes with empagliflozin in heart failure
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure in patients regardless of the presence or absence of …
hospitalization for heart failure in patients regardless of the presence or absence of …
[HTML][HTML] Sotagliflozin in patients with diabetes and recent worsening heart failure
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure or death from cardiovascular causes among patients with …
hospitalization for heart failure or death from cardiovascular causes among patients with …
[HTML][HTML] Sotagliflozin in patients with diabetes and chronic kidney disease
Background The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …
Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial
Background: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with
heart failure with reduced ejection fraction, but additional information is needed about …
heart failure with reduced ejection fraction, but additional information is needed about …
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
V Quagliariello, M De Laurentiis, D Rea… - Cardiovascular …, 2021 - Springer
Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …
Neuroprotective effect of SGLT2 inhibitors
A Pawlos, M Broncel, E Woźniak, P Gorzelak-Pabiś - Molecules, 2021 - mdpi.com
Patients with diabetes are at higher risk of cardiovascular diseases and cognitive
impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin …
impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin …
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
M Packer - Nature Reviews Cardiology, 2023 - nature.com
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by
direct action on the failing heart that is independent of changes in renal tubular function. In …
direct action on the failing heart that is independent of changes in renal tubular function. In …